Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus
A legfontosabb adatok
- Ki végzi
- Centre Hospitalier Universitaire de Nīmes
- Hol
- Franciaország7 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 1/2. fázis
- Résztvevők
- 60 fő, tervezett
- Kezdés
- 2026. szept. 1.
- Várható befejezés
- 2028. nov.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Topical anti-Staphylococcus bacteriophage therapy
- Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy
- A regiszteradat frissítve
- 2026. március 20.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with type 1 or type 2 diabetes who have an infected foot wound with S. aureus. It compares a phage cocktail put on the wound with a placebo, both added to standard treatment.
- Életkor
- 18 years and older.
- Nem
- All sexes.
- A betegség stádiuma
- A nerve-damage (neuropathic) foot wound below the ankle, present for >2 weeks, with a surface area ≥ 0,5 cm2. SINBAD class S (0 or 1), I (0 or 1), N (1), B (1), A (0 or 1), D (1). IWGDF/IDSA grade 2 or 3 infection with no bone infection. No poor blood flow, or only non-critical: ankle arterial pressure > 50 mm Hg, toe systolic pressure > 30 mm Hg, or TcpO2 > 30 mm Hg.
- Korábbi kezelés
- No other trial in the past three months.
- Biomarker vagy leletérték
- The wound must be infected by S. aureus (MSSA or MRSA), alone or with other bacteria, up to 3 bacteria in total. A phagogram test must show the strains respond to at least one phage (PP1493 and/or PP1815). Negative pregnancy test before treatment.
A részvétel fő kizáró okai
- Bone infection (osteomyelitis) or joint inflammation (arthritis) linked to the wound
- Wound not infected by S. aureus, or infected by more than 3 bacteria
- Pregnant, giving birth or breastfeeding, or planning pregnancy during treatment and 1 month after
- Not willing to use effective birth control during and 1 month after the study drug
- Under guardianship or judicial protection
A regiszter feltételei, szó szerint
Mind a 29 feltétel megnézéseKevesebb
Egyéb feltételek
- Participant pre-inclusion criteria:
- The patient must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- The patient is at least 18 years old
- The patient has type 1 or type 2 diabetes
- The patient is hospitalized/consulting in a participating centre
- The patient has a wound below the ankle that has be evolving for >2 weeks
- The patient has a neuropathic foot wound, classified S (0 or 1), I (0 or 1), N (1), B (1), A (0 or1) and D (1) according to the SINBAD classification,; without ischaemia or with non-critical ischaemia defined by: ankle arterial pressure > 50 mm Hg or toe systolic arterial pressure > 30 mm Hg or TcpO2 > 30 mm Hg ); with a surface area ≥ 0,5 cm2; With IWGDF/IDSA grade 2 or 3 infection without osteomyelitis (normal radiography*)
- Females of childbearing potential or Sexually active males with partner of childbearing potential: commitment to consistently and correctly use an acceptable method of birth control (oral, transdermal, systemic or implant contraception birth control, intrauterine devices) for 1 month after the last study drug administration
- Negative pregnancy test must be obtained before starting any experimental drug
- Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhea duration at least 12 months); Participant final inclusion criteria:
- The patient has a neuropathic foot wound:; Classified S (0 or 1), I (0 or 1), N (1), B (1), A (0 or1) and D (1) according to the SINBAD classification,
- without ischaemia or with non-critical ischaemia defined by: ankle arterial pressure > 50 mm Hg or toe systolic arterial pressure > 30 mm Hg or TcpO2 > 30 mm Hg )
- with a surface area ≥ 0,5 cm2; With IWGDF/IDSA grade 2 or 3 infection without osteomyelitis
- The patient's wound is monoinfected by methicillin-resistant or susceptible S. aureus (MSSA or MRSA ), or infected by MSSA or MRSA and other bacteria (a total of 3 bacteria when accounting for MSSA or MRSA)
- The Phagogram of the patient demonstrated that the strains are susceptible to at least one phage(PP1493 and/or PP1815); Participant pre-exclusion criteria:
- The patient is participating in, or has participated in over the past three months, another trial
- The patient is participating in, or has participated in over the past three months, another study that may interfere with the results or conclusions of this study
- The patient is in an exclusion period determined by a previous study
- The patient is under judicial protection, or is an adult under guardianship
- It is impossible to correctly inform the patient
- The patient refuses to sign the consent
- The patient is pregnant, parturient or breastfeeding. Patients should not be enrolled if they plan to become pregnant during the treatment period and 1 month after the last administration of study drug
- Women/Men refusing to use an effective contraception during and1 month after the last administration of study drug; Participant final exclusion criteria:
- The patient refuses to participate to the study
- The patient is pregnant, parturient or breastfeeding. Patients should not be enrolled if they plan to become pregnant during the treatment period and 1 month after the last administration of study drug
- Women/Men refusing to use an effective contraception during and1 month after the last administration of study drug
- Patients with diabetic foot wounds associated with clinical or radiographic signs of arthritis or osteomyelitis*
- Patient is not infected by S. aureus or infected by more than 3 bacteria even if the culture isolates a S. aureus
Ez a vizsgálat jelenleg itt érhető el: Franciaország.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The primary objective of this study is to compare the efficacy of standard treatment associated with a topical anti-staphylococcal bacteriophage cocktail versus standard treatment plus placebo for diabetic foot ulcers monoinfected by methicillin-resistant or susceptible S. aureus (MRSA or MSSA) as measured by the relative reduction in wound surface area (%) at 12 weeks.
A vizsgálat 2 csoportja
- Phage therapyA vizsgált kezelés
Patients randomized to this arm will have phage therapy. Intervention: Topical anti-Staphylococcus bacteriophage therapy
Kezelés: Topical anti-Staphylococcus bacteriophage therapy
- PlaceboPlacebo, összehasonlításként
Patients randomized to this arm will have placebo therapy anologous to that of the experimental arm. Intervention: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy
Kezelés: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- Comparison of the Efficacy of Standard Treatment Associated With Phage Therapy Versus Standard Treatment Plus Placebo for Diabetic Foot Ulcers Monoinfected by Staphylococcus Aureus: a Randomized, Multi-centre, Controlled, 2-parallel-group, Double-blind, Superiority Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2026. március 20.